01 Pregnant women are more likely to sign up for PROM testing during their pregnancy for reassurance and monitoring of preterm birth symptoms as preterm births and their consequences become more well-known, stimulating preterm birth and prom testing market growth.Premature Rupture of Membrane is referred to as PROM. It is one of the primary causes of preterm deliveries and a usual pregnancy difficulty. Preterm birth and premature rupture of membrane (PROM) tests are combined into preterm birth and PROM testing. Hospitalization and expectant management are two possible care and therapy options for premature membrane rupture. Very rarely, the membrane may close and stop leaking fluid. Gynaecologists look for signs of premature labour, including pelvic pressure, vaginal spotting or bleeding, cramping or frequent contractions, vaginal discharge, and fluid leaking.Over a few hours, a pelvic exam is repeatedly carried out to track contractions and identify cervix changes. Due to these tests' high degree of accuracy, preterm labour can be detected early, reducing the risk of infant morbidity and death, reducing the length of stay for high-risk patients, and avoiding unnecessary medical costs. Traditional preterm birth testing methods include fetal fibronectin (fFN), pelvic examination, blood test, ultrasound, and sterile speculum inspection (pooling).
May 2026 Hologic expanded its prenatal diagnostics portfolio with advanced testing solutions for identifying women at risk of preterm birth and premature rupture of membranes (PROM). The new assays improve diagnostic accuracy and support timely clinical intervention. They strengthen the company's women's health diagnostics business.
April 2026 QIAGEN introduced upgraded molecular testing solutions for maternal and fetal health applications. The enhancements provide faster and more reliable results for pregnancy-related diagnostic testing. They reinforce the company's prenatal diagnostics portfolio.
February 2026 Abbott expanded its maternal health diagnostics portfolio with improved laboratory testing solutions for pregnancy complications. The new technologies support earlier risk assessment and better clinical decision-making. They strengthen the company's women's health offerings.
October 2025 Sera Prognostics advanced the commercialization of its biomarker-based pregnancy risk assessment platform. The technology helps identify women at increased risk of spontaneous preterm birth. It reinforces the company's leadership in maternal health diagnostics.